Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of ataluren in nonsense-mutation cystic fibrosis
NL-OMON36381Phase 3Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ataluren in cystic fibrosis (CF), sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety profile. Started Aug 2010; status: active, not recruiting.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON36381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36381.